BioCardia, Inc. Announces FDA Acceptance of Pre-Submission Package for Helix Transendocardial Delivery Catheter
Key Points:
- BioCardia, Inc. (NASDAQ: BCDA) has announced that the U.S. Food and Drug Administration (FDA) has accepted its pre-submission package for the approval of the Helix Transendocardial Delivery Catheter (“Helix”), intended for intramyocardial therapeutic and diagnostic agent delivery.
- This marks a significant milestone for BioCardia’s regulatory pathway and may accelerate the timeline for eventual FDA approval.
- The Helix catheter is designed to deliver both therapeutic and diagnostic agents directly into the myocardium, supporting treatment options for heart failure, chronic myocardial ischemia, and acute myocardial infarction.
Details for Investors:
- The acceptance of the pre-submission package by the FDA is a critical step in BioCardia’s product development process. It signals that the company is moving closer to regulatory clearance for its Helix catheter, which could open new commercial opportunities in cardiovascular therapies.
- The press release, attached as Exhibit 99.1 to the 8-K filing, clarifies that this information is being furnished and not filed, which means it is not subject to the liabilities of Section 18 of the Securities Exchange Act of 1934.
- BioCardia’s common stock (trading symbol: BCDA) is listed on the Nasdaq Capital Market. Regulatory progress such as FDA acceptance often has a material impact on share price, especially for companies in the life sciences and medical device sectors.
- Additional upcoming catalysts mentioned in the press release include:
- CardiAMP for Ischemic HFrEF: FDA Q-Sub on Approval Pathway scheduled for Q1.
- CardiAMP for Ischemic HFrEF: Japan PMDA Formal Clinical Consultation expected in Q2.
- CardiAMP for Chronic Myocardial Ischemia: Oral Presentation at Euro PCR planned for Q2.
- These events represent further regulatory and clinical milestones, each potentially influencing investor sentiment and market valuation.
Important Shareholder Information:
- FDA acceptance of a pre-submission package is often interpreted as positive progress and can be price-sensitive, as it may shorten the time to market for the Helix catheter.
- Any delays, unexpected expenditures, or failure to secure additional funding could impact BioCardia’s ability to pursue its business and product development plans, as stated in the forward-looking statements section.
- The company’s liquidity, ability to raise additional capital, and successful progression of clinical trials are noted risk factors that could materially affect actual results and share value.
- Investors are encouraged to monitor further regulatory updates and clinical trial progress, as these are likely to influence BCDA’s stock price in the short and medium term.
Corporate Contacts:
- Media Contact: Miranda Peto, Investor Relations ([email protected], 650-226-0120)
- Investor Contact: David McClung, Chief Financial Officer ([email protected], 650-226-0120)
Forward-Looking Statements Disclaimer:
This article contains forward-looking statements regarding BioCardia, Inc.’s intentions, projections, and expected regulatory and clinical milestones. These statements are subject to numerous risks and uncertainties, including but not limited to regulatory approvals, product development, financial condition, ability to raise additional funds, and success of clinical trials. Actual results may differ materially from those expressed or implied. Investors should review BioCardia’s latest filings with the SEC, including the Form 10-K and subsequent Form 10-Q reports, for further risk factors and detailed disclosures. BioCardia expressly disclaims any intent or obligation to update forward-looking statements except as required by law.
View BioCardia, Inc. Historical chart here
